Financial Survey: Forte Biosciences (NASDAQ:FBRX) vs. Oculis (NASDAQ:OCS)

Oculis (NASDAQ:OCS) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Earnings and Valuation

This table compares Oculis and Forte Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$780,000.00	1,985.07	-$97.43 million	($2.52)	-11.73
Forte Biosciences	N/A	N/A	-$35.48 million	($3.32)	-8.57

Forte Biosciences has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

22.3% of Oculis shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and target prices for Oculis and Forte Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1	0	8	0	2.78
Forte Biosciences	1	0	3	0	2.50

Oculis currently has a consensus target price of $41.50, suggesting a potential upside of 40.39%. Forte Biosciences has a consensus target price of $67.00, suggesting a potential upside of 135.58%. Given Forte Biosciences’ higher possible upside, analysts clearly believe Forte Biosciences is more favorable than Oculis.

Volatility and Risk

Oculis has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 3.22, suggesting that its share price is 222% more volatile than the S&P 500.

Profitability

This table compares Oculis and Forte Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oculis	-12,915.42%	-80.82%	-61.18%
Forte Biosciences	N/A	-75.64%	-65.94%

Summary

Forte Biosciences beats Oculis on 8 of the 13 factors compared between the two stocks.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

About Forte Biosciences

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.